Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about AUPH, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Voclosporin FDA approved Jan 2021 · Lupkynis |
Lupus Nephritis | Phase 4 · NCT07611214 | Recruiting |
| mycophenolic acid analog (MPAA) | Lupus Nephritis | Phase 4 · NCT07611214 | Recruiting |
| Corticosteroid | Lupus Nephritis | Phase 4 · NCT07611214 | Recruiting |
| 0.10% VOS | Dry Eye Syndrome | Phase 2/3 · NCT04147650 | Completed |
| Cyclosporine | Psoriasis | Phase 3 · NCT00408187 | Completed |
| 0.20% VOS | Dry Eye Syndrome | Phase 2/3 · NCT04147650 | Completed |
| 0.05% Voclosporin Ophthalmic Solution (VOS) | Dry Eye Syndrome | Phase 2/3 · NCT04147650 | Completed |
| Aritinercept | Myasthenia Gravis, Generalized | Phase 1/2 · NCT07596901 | Recruiting |
| Voclosporin Ophthalmic Solution | Dry Eye | Phase 2 · NCT03597139 | Completed |
Also used in these trials (approved or third-party drugs, not AUPH's own candidates): Belimumab, Tacrolimus Extended-Release, Simvastatin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
AUPH holds $486.5M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AUPH files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Kevin Tang Chief Executive Officer, Director, 10% o · +10,000 options |
Insider | 13,044,106 | 9.73% | 2026-05-29 |
| TANG CAPITAL MANAGEMENT, LLC | 5%+ holder (13D) | 13,044,106 | 9.73% | 2026-06-02 |
| Peter Greenleaf Chief Executive Officer, Director · +772,397 options |
Insider | 1,840,379 | 1.37% | 2026-02-27 |
| Matthew Maxwell Donley Chief Operating Officer · +97,256 options |
Insider | 680,299 | 0.51% | 2026-02-27 |
| Stephen P. Robertson Chief Legal Officer · +98,813 options |
Insider | 576,981 | 0.43% | 2026-11-13 |
| Joseph M Miller Chief Financial Officer · +95,700 options |
Insider | 576,421 | 0.43% | 2026-02-27 |
| Greg Keenan SVP, Chief Medical Officer · +67,870 options |
Insider | 154,449 | 0.12% | 2026-03-06 |
| Ryan Cole Chief Operating Officer · +70,230 options |
Insider | 116,144 | 0.09% | 2026-05-18 |
| Michael S Hearne Chief Financial Officer · +70,230 options |
Insider | 116,144 | 0.09% | 2026-05-18 |
| Jeffrey Allen Bailey Director · +61,416 options |
Insider | 22,775 | 0.02% | 2025-11-21 |
| Craig A Johnson Director · +61,416 options |
Insider | 14,592 | 0.01% | 2025-11-21 |
Share count 133,998,660 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AUPH and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →